Status:
UNKNOWN
Characterisation of Primary Progressives Aphasias
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Aphasia Primary Progressive
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Primary progressive aphasias (PPA) represent a challenging group of degenerative language diseases that has led to growing interest in the scientific and medical community. However, a full-blown cogni...
Detailed Description
Rationale Primary progressive aphasia (PPA) is an umbrella term which identifies a group of neurodegenerative diseases characterized by language deficits. By definition, language disorders are isolate...
Eligibility Criteria
Inclusion
- Inclusion criteria A) Patients responding to current diagnostic criteria for Primary Progressive Aphasia
- Language disorders without important impairments of other cognitive functions
- Insidious onset and gradual progression
- Diagnostic criteria for non fluent PPA
- Non fluent language out-put
- Phonemic paraphasias and/or agrammatism
- Relative preservation of speech comprehension
- Diagnostic criteria for fluent PPA
- Fluent language out-put
- Impairment of the access to word meanings leading to comprehension disorders and naming deficits
- Associative agnosia and/or prosopagnosia may be present. This will allow for the inclusion of patients with multi-modal disorders of meaning (semantic dementia patients).
- Diagnostic criteria for logopenic PPA
- Speech out-put with frequent interruptions due to word finding deficits
- Disorders of sentence comprehension and repetition due to impairment of working memory B) Patients at age of majority C) Patients having given informed and written consent
- Exclusion criteria A) Cognitive criteria
- Aphasia severity rating scale of the BDAE \< 3
- MMS \< 20
- Severe disorders of executive functions, praxis or episodic memory B) MADRS ≥ 20 (major depression as defined by criteria of the DSM-IV-R) C) Patients whose mother tongue is not French D) Patients affected by of other neurological diseases than PPA or general diseases or physical problems that may impact on cognitive functioning E) Counter-indication for MRI or PET scanning (the lumbar puncture is optional / separated informed consent) F) MRI compatible with pathological processes other than PPA. A mild to moderate leucoaraiosis will not been considered as an exclusion criteria (only patients at stage \> 2 will be excluded from the study) G) Non affiliation at the French healthcare system
Exclusion
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2017
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT02297035
Start Date
March 1 2012
End Date
November 1 2017
Last Update
August 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Département de Neurologie - Centre des maladies neurologiques, cognitives et comportementales
France, France, 75003